MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.40
-0.03
-0.36%
Opening 11:32 06/09 EDT
OPEN
8.52
PREV CLOSE
8.43
HIGH
8.63
LOW
8.39
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
11.23
52 WEEK LOW
6.00
MARKET CAP
2.13B
P/E (TTM)
-4.7284
1D
5D
1M
3M
1Y
5Y
1D
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Weakness
Simply Wall St · 1d ago
Weekly Report: what happened at BCRX last week (0601-0605)?
Weekly Report · 1d ago
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story?
Simply Wall St · 3d ago
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
Barchart · 3d ago
These 10 mid-cap U.S. healthcare giants rank among the market's most attractively valued stocks
Seeking Alpha · 06/01 14:10
Weekly Report: what happened at BCRX last week (0525-0529)?
Weekly Report · 06/01 09:52
Could BioCryst (BCRX) HAE Data at EAACI Quietly Redefine Its Core Investment Story?
Simply Wall St · 05/29 09:11
BioCryst Pharma To Present Seven Abstracts From Hereditary Angioedema Portfolio At Annual Meeting Of EAACI 2026
Benzinga · 05/27 11:25
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Its portfolio also includes navenibart, which is a late-stage, long-acting plasma kallikrein inhibitor. It has also obtained an early-stage program for atopic dermatitis, STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.